Top 5 Vendors in the Global Dyslipidemia Drugs Market from 2017 to 2021: Technavio

Technavio has announced the release of their 'Global Dyslipidemia Drugs Market 2017-2021' report. (Graphic: Business Wire)

???pagination.previous??? ???pagination.next???

LONDON--()--Technavio has announced the top five leading vendors in their recent global dyslipidemia drugs market 2017-2021 report. This market research report also lists 17 other prominent vendors that are expected to impact the market during the forecast period.

Competitive vendor landscape

According to the research analysis, the global dyslipidemia drugs market is highly competitive with the presence of numerous small and large vendors. The major vendors in the market are Aegerion Pharmaceuticals, AstraZeneca, Merck, Pfizer, and Sanofi. Occasional spurts of competition have been witnessed from local manufacturers present in various countries. New players are also entering the market as they have strong growth opportunities. Companies like Amgen, HanAll BioPharma, Kowa Pharmaceuticals, CJ HealthCare, Catabasis Pharmaceuticals, JW Pharmaceuticals, and Esperion Pharmaceuticals are expected to enter the market during the forecast period.

“The global dyslipidemia drugs market will grow at a steady pace due to an increase in the incidence of hypercholesterolemia and chronic diseases. Currently, hypercholesterolemia therapies require lifelong administration and have undesirable side effects. Therefore, there is an increasing demand for improved drugs. The availability of promising drugs, along with changed treatment guidelines, will contribute to drive the growth of the market during the forecast period,” says Sapna Jha, lead cardiovascular and metabolic disorders analyst from Technavio.

Looking for more research on this report? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Technavio healthcare and life sciences market research analysts identify the following key vendors:

Aegerion Pharmaceuticals

Aegerion Pharmaceuticals, a subsidiary of Novelion Therapeutics, develops and markets innovative therapies for individuals with rare debilitating diseases. The company leverages its strong portfolio led by its leading hypercholesterolemia drug, JUXTAPID. The clinical trials in the hypercholesterolemia area will enable the company to develop new products.

AstraZeneca

AstraZeneca researches, develops, manufactures, and distributes medicines to treat CVDs and metabolic diseases, oncology diseases, respiratory diseases, inflammation, autoimmunity disorders and infections, neurological diseases, and gastrointestinal diseases. The company is focusing on its early-stage pipeline through novel science and technology.

Merck

Merck researches, develops, manufactures, and markets prescription medicines, biologic therapies, vaccines, and animal health products. The company leverages its portfolio led by hypercholesterolemia drugs such as Zetia and Vytorin. The company focuses on advancing its product pipeline to develop new treatments.

Pfizer

Pfizer produces, manufactures, and develops pharmaceutical products for arthritis, CVDs, metabolic disorders, infectious diseases, and respiratory diseases. The company has a strong presence in the market through its cholesterol product, Lipitor. The company focuses on implementing inorganic growth strategies to fuel its market presence.

Sanofi

Sanofi researches, develops, and markets therapeutic solutions and healthcare products. It has an established presence in the hypercholesterolemia market with offerings such as Praluent and Kynamro. The company focuses on collaborating with key players in the healthcare sector.

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like cardiovascular devices, in-vitro diagnostics, and oncology. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com